Insider Selling: GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells 402 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 402 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $90.05, for a total transaction of $36,200.10. Following the completion of the sale, the chief financial officer now directly owns 5,044 shares of the company’s stock, valued at $454,212.20. This represents a 7.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Monday, March 17th, Kevin Feeley sold 3,749 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total transaction of $362,565.79.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The stock was sold at an average price of $94.72, for a total value of $87,331.84.
• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total value of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The stock was sold at an average price of $93.82, for a total value of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The stock was sold at an average price of $76.04, for a total transaction of $108,737.20.

GeneDx Trading Down 4.1 %

NASDAQ WGS traded down $4.01 during trading hours on Monday, reaching $94.46. The company’s stock had a trading volume of 668,407 shares, compared to its average volume of 612,654. GeneDx Holdings Corp. has a 52 week low of $7.72 and a 52 week high of $115.60. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The stock has a market cap of $2.65 billion, a P/E ratio of -48.19 and a beta of 1.91. The firm has a fifty day simple moving average of $84.69 and a 200-day simple moving average of $70.37.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.66. The company had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. Equities analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeneDx

Institutional investors have recently made changes to their positions in the stock. William Blair Investment Management LLC bought a new position in shares of GeneDx during the fourth quarter worth about $51,496,000. Lord Abbett & CO. LLC acquired a new stake in GeneDx during the 4th quarter valued at approximately $48,458,000. Summit Partners Public Asset Management LLC raised its holdings in GeneDx by 336.9% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 755,564 shares of the company’s stock worth $58,073,000 after purchasing an additional 582,619 shares during the last quarter. Science & Technology Partners L.P. acquired a new position in shares of GeneDx in the 4th quarter worth approximately $30,821,000. Finally, Fred Alger Management LLC bought a new stake in shares of GeneDx in the 3rd quarter valued at $16,731,000. Institutional investors own 61.72% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on WGS. The Goldman Sachs Group boosted their price objective on shares of GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research report on Wednesday, February 19th. TD Cowen raised their price target on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $72.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.